Great question. This is definitely a topic about which there often seems to be various opinions, recommendations, suggestions, etc., where such interpretive variability can lead to compliance problems. But in FDA's eyes, the issue and associated requirements are abundantly clear. Specifically, FDA officially considers ad/promo materials to be labeling. And by FDA definition, labeling is part of the total finished design output. And where there's design output, there must also be corresponding design planning, inputs, verification, validation, transfer, and design change control.
------------------------------
Kevin Randall, ASQ CQA, RAC (U.S., Europe, Canada)
Principal Consultant
Ridgway, CO
United States
© Copyright 2021 by ComplianceAcuity, Inc. All rights reserved.
------------------------------
Original Message:
Sent: 12-May-2021 14:53
From: Anonymous Member
Subject: FDA Design Controls and Promo/Advertising Materials
This message was posted by a user wishing to remain anonymous
Seeking advice regarding whether marketing and advertising development would fall under FDA QS design controls. Do medical device companies process all marketing materials through the design control process or are there exceptions?
thanks for your help
mike